HRP20070452T3 - Sulfonamidni derivati namijenjeni liječenju bolesti - Google Patents

Sulfonamidni derivati namijenjeni liječenju bolesti

Info

Publication number
HRP20070452T3
HRP20070452T3 HR20070452T HRP20070452T HRP20070452T3 HR P20070452 T3 HRP20070452 T3 HR P20070452T3 HR 20070452 T HR20070452 T HR 20070452T HR P20070452 T HRP20070452 T HR P20070452T HR P20070452 T3 HRP20070452 T3 HR P20070452T3
Authority
HR
Croatia
Prior art keywords
alkyl
group
cycloalkyl
diseases
treatment
Prior art date
Application number
HR20070452T
Other languages
English (en)
Inventor
D Brown Alan
James Kim
A.L. Lane Charlotte
B. Moses Ian
M. Thomson Nicholas
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43063961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20070452(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406388A external-priority patent/GB0406388D0/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HRP20070452T3 publication Critical patent/HRP20070452T3/hr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40Y being a hydrogen or a carbon atom
    • C07C323/42Y being a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Spoj opće formule (1): naznačen time što (CH2)n-C(=O)Q1 skupina je na meta ili para položaju, R1 i R2 se neovisno bira između H i C1-C4 alkila, n je 0, 1 ili 2, a Q1 je skupina koju se bira između: ,i skupine *-NR11-Q2-A, gdje p je 1 ili 2, Q2 je C1-C4 alkilen, R11 je H ili C1-C4 alkil, a A je piridil, C3-C10 cikloalkil, gdje je navedeni cikloalkil izborno premošten s jednim ili više atoma ugljika, tetrahidropiranil, piperidinil, izborno supstitutiran s benzilom, tetrahidrotiopiranil ili skupinagdje R3, R4, R5, R6 i R7 su isti ili različiti i bira ih se između H, C1-C4 alkila, OR5, SR9, halogena, CN, CF3, OCF3, COOR9, SO2NR9R10, CONR9R10, NR9R10, NHCOR10 i fenila; gdje R8 je C1-C4 alkil, R8i R10 su isti ili različiti i bira ih se između Hili C1-C4 alkila, a * predstavlja mjesto vezanja na karbonilnu skupinu; ili, ako je to prikladno, njegove farmaceutski prihvatljive soli i(li) izomeri, tautomeri, solvati ili njihove izotopne varijante. Patent sadrži još 32 patentna zahtjeva.
HR20070452T 2004-01-22 2007-09-27 Sulfonamidni derivati namijenjeni liječenju bolesti HRP20070452T3 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290168 2004-01-22
GB0406388A GB0406388D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60025904P 2004-08-09 2004-08-09
PCT/IB2005/000112 WO2005080324A1 (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases

Publications (1)

Publication Number Publication Date
HRP20070452T3 true HRP20070452T3 (hr) 2008-02-29

Family

ID=43063961

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20070452T HRP20070452T3 (hr) 2004-01-22 2007-09-27 Sulfonamidni derivati namijenjeni liječenju bolesti

Country Status (41)

Country Link
US (1) US7351742B2 (hr)
EP (1) EP1708992B1 (hr)
JP (1) JP4036343B2 (hr)
KR (1) KR100785580B1 (hr)
CN (1) CN1910144B (hr)
AP (1) AP2378A (hr)
AR (1) AR047510A1 (hr)
AT (1) ATE369333T1 (hr)
AU (1) AU2005214154B2 (hr)
BR (1) BRPI0507041A (hr)
CA (1) CA2553293C (hr)
CO (1) CO5720993A2 (hr)
CY (1) CY1106894T1 (hr)
DE (1) DE602005001929T2 (hr)
DK (1) DK1708992T3 (hr)
DO (1) DOP2005000004A (hr)
EA (1) EA009735B1 (hr)
EC (1) ECSP066701A (hr)
ES (1) ES2289691T3 (hr)
GE (1) GEP20084452B (hr)
HK (1) HK1096083A1 (hr)
HN (1) HN2005000030A (hr)
HR (1) HRP20070452T3 (hr)
IL (1) IL176629A (hr)
MA (1) MA28303A1 (hr)
ME (1) ME00557A (hr)
MY (1) MY139690A (hr)
NL (1) NL1028086C2 (hr)
NO (1) NO20063761L (hr)
NZ (1) NZ548235A (hr)
OA (1) OA13361A (hr)
PA (1) PA8621901A1 (hr)
PE (1) PE20050765A1 (hr)
PL (1) PL1708992T3 (hr)
PT (1) PT1708992E (hr)
RS (1) RS50538B (hr)
SI (1) SI1708992T1 (hr)
TW (1) TWI273099B (hr)
UA (1) UA82283C2 (hr)
UY (1) UY28724A1 (hr)
WO (1) WO2005080324A1 (hr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
MX2008000794A (es) * 2005-07-18 2008-03-18 Pfizer Ltd Procedimiento para la preparacion de derivados de sulfonamida.
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AP2402A (en) 2006-03-20 2012-04-30 Pfizer Ltd Amine derivatives.
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
KR20090050104A (ko) * 2006-10-04 2009-05-19 화이자 리미티드 아드레날린성 효능제 및 무스카린성 길항제로서 술폰아미드 유도체
DE102007018151A1 (de) 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
US7713463B1 (en) * 2007-11-13 2010-05-11 Nuvasive, Inc. Method of manufacturing embroidered surgical implants
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
US8263623B2 (en) * 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
CA2748331C (en) 2008-12-30 2016-08-02 Pulmagen Therapeutics (Inflammation) Limited Sulfonamide compounds for the treatment of respiratory disorders
AU2010239522B2 (en) 2009-04-23 2015-07-02 Theravance Biopharma R&D Ip, Llc Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
WO2010136940A1 (en) 2009-05-29 2010-12-02 Pfizer Limited Novel glucocorticoid receptor agonists
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
SI2718280T1 (sl) 2011-06-10 2015-12-31 Chiesi Farmaceutici S.P.A. Spojine, ki imajo aktivnost antagonista muskarinskega receptorja in beta2-adrenergičnega receptorja
EP2928890B1 (en) 2012-12-06 2018-02-28 Chiesi Farmaceutici S.p.A. Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
PT3345904T (pt) 2012-12-06 2020-09-07 Chiesi Farm Spa Compostos com atividade antagonista dos recetores muscarínicos e agonista dos recetores adrenérgicos beta2
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US6362371B1 (en) 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
JP2005527618A (ja) * 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ2アドレナリン作動性レセプターアゴニスト
EP1477167A1 (en) * 2003-05-15 2004-11-17 Pfizer Limited [(2-hydroxy-2-(4-hydroxy-3-hydroxymethylphenyl)-ethylamino)-propyl] phenyl derivatives as beta2 agonists

Also Published As

Publication number Publication date
US7351742B2 (en) 2008-04-01
PL1708992T3 (pl) 2007-12-31
ME00557A (en) 2011-12-20
NL1028086C2 (nl) 2006-05-09
WO2005080324A8 (en) 2006-02-23
NO20063761L (no) 2006-10-23
HN2005000030A (es) 2009-04-20
TW200530164A (en) 2005-09-16
UA82283C2 (uk) 2008-03-25
CY1106894T1 (el) 2012-09-26
MA28303A1 (fr) 2006-11-01
AU2005214154A1 (en) 2005-09-01
NL1028086A1 (nl) 2005-07-25
AP2378A (en) 2012-03-08
ATE369333T1 (de) 2007-08-15
SI1708992T1 (sl) 2007-12-31
JP4036343B2 (ja) 2008-01-23
IL176629A0 (en) 2006-10-31
WO2005080324A1 (en) 2005-09-01
RS50538B (sr) 2010-05-07
TWI273099B (en) 2007-02-11
CO5720993A2 (es) 2007-01-31
BRPI0507041A (pt) 2007-06-12
PA8621901A1 (es) 2006-03-24
EA009735B1 (ru) 2008-02-28
AP2006003671A0 (en) 2006-06-30
US20050171147A1 (en) 2005-08-04
CN1910144B (zh) 2010-06-09
DE602005001929T2 (de) 2007-12-06
PE20050765A1 (es) 2005-10-31
CA2553293C (en) 2010-12-14
AU2005214154B2 (en) 2008-01-24
OA13361A (en) 2007-04-13
EP1708992B1 (en) 2007-08-08
AR047510A1 (es) 2006-01-25
JP2007518790A (ja) 2007-07-12
ECSP066701A (es) 2006-10-31
DE602005001929D1 (de) 2007-09-20
HK1096083A1 (en) 2007-05-25
EA200601141A1 (ru) 2007-02-27
ES2289691T3 (es) 2008-02-01
MY139690A (en) 2009-10-30
CN1910144A (zh) 2007-02-07
KR100785580B1 (ko) 2007-12-13
GEP20084452B (en) 2008-08-10
NZ548235A (en) 2010-05-28
EP1708992A1 (en) 2006-10-11
DOP2005000004A (es) 2005-07-31
UY28724A1 (es) 2005-08-31
KR20060127073A (ko) 2006-12-11
DK1708992T3 (da) 2007-11-05
IL176629A (en) 2011-04-28
PT1708992E (pt) 2007-11-16
CA2553293A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
HRP20070452T3 (hr) Sulfonamidni derivati namijenjeni liječenju bolesti
RS50561B (sr) Derivati sulfonamida za lečenje bolesti
AR048322A1 (es) Compuestos para el tratamiento de afecciones inflamatorias, alergicas y respiratorias
MXPA05011666A (es) Compuestos de pirazol-amida aril-sustituidos utiles como inhibidores de cinasa.
CR10034A (es) Derivados de oxadiazol
ME01421B (me) 5-supstituisani derivati kinazolinona kao protivtumorska sredstva
HRP20030448B1 (en) Ortho-substituted nitrogen-containing bisaryl compounds used as potassium channel inhibitors
KR960010000A (ko) 종양괴사인자(tnf)생성 저해제로서의 카테콜 디에테르 화합물
HUP0302221A2 (hu) 4-Amino-kinazolinok, eljárás előállításukra, alkalmazásuk és azokat tartalmazó gyógyszerkészítmények
CO5700776A2 (es) Compuestos utiles para el tratamiento de enfermedades
MXPA03011244A (es) Nuevos derivados de indol con afinidad por el receptor 5-ht6.
AR045255A1 (es) Derivados de 1,2 benzodiazol
MX2019012336A (es) Compuestos inhibidores del transportador vesicular de monoaminas 2 (vmat2) y composiciones de los mismos.
CO5611152A2 (es) Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen
DK1633340T3 (da) Forbindelser til behandling af stofskifteforstyrrelser
CO5690608A2 (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
RS51557B (en) 4H-1,2,4-TRIAZIN-5-ONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE AS ALFA 7 NICOTINE ACETYLHOLINE RECEPTORS
AP9901578A0 (en) Sulfonylbenzene compounds as anti-inflammatory/analgesic agents.
WO2000032578A8 (en) Benzimidazole compounds that are vitronectin receptor antagonists
RS50772B (sr) Pentafluorsulfanil-benzoilgvandini, postupak za njihovu proizvodnju, njihova primena u svojstvu leka ili dijagnostičkog sredstva kao i lek koji sadrži ova jedinjenja
ATE550332T1 (de) 4-imidazolin-2-onverbindungen als p38-map- kinaseinhibitors
TW200633710A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
ECSP077394A (es) Compuestos aromáticos de arilsulfonilmetil o arilsulfonamida sustituida apropiados para tratar trastornos que responden a la modulación del receptor de dopamina d3
RS50289B (sr) Novi razgranati supstituisani amino derivati od 3-amino-1- fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
BR0208823A (pt) Composto, método de tratamento de distúrbios que são remediados ou aliviados pela atividade de agonista de vasopressina em um mamìfero necessitando do mesmo, e, composição farmacêutica